Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
Umesh C. Sharma,Saraswati Pokharel,Thomas J. van Brakel,Jop H. van Berlo,Jack P.M. Cleutjens,Blanche Schroen,Sabine André,Harry J.G.M. Crijns,Hans J. Gabius,Jos G. Maessen,Yigal M. Pinto +10 more
966
TL;DR: Galectin-3, a macrophage-derived mediator, induces cardiac fibroblast proliferation, collagen deposition, and ventricular dysfunction, which implies that HF therapy aimed at inflammatory responses may need to be targeted at the early stages of HF and probably needs to antagonize multiple inflammatory mediators, including galectIn-3.
read more
Abstract: Background— Inflammatory mechanisms have been proposed to be important in heart failure (HF), and cytokines have been implicated to add to the progression of HF. However, it is unclear whether such mechanisms are already activated when hypertrophied hearts still appear well-compensated and whether such early mechanisms contribute to the development of HF. Methods and Results— In a comprehensive microarray study, galectin-3 emerged as the most robustly overexpressed gene in failing versus functionally compensated hearts from homozygous transgenic TGRmRen2-27 (Ren-2) rats. Myocardial biopsies obtained at an early stage of hypertrophy before apparent HF showed that expression of galectin-3 was increased specifically in the rats that later rapidly developed HF. Galectin-3 colocalized with activated myocardial macrophages. We found galectin-3-binding sites in rat cardiac fibroblasts and the extracellular matrix. Recombinant galectin-3 induced cardiac fibroblast proliferation, collagen production, and cyclin D1...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
State of the Art: Newer biomarkers in heart failure
TL;DR: This review examines the best emerging candidates for clinical assessment and management of patients with HF by identifying markers that mirror the complex pathophysiology of heart failure at various levels.
Decision: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R2/PR10
06 Nov 2023
TL;DR: Precision therapy in dilated cardiomyopathy holds promise for improving patient outcomes and reducing costs by shifting the focus to patient-specific treatment decisions and increasing the use of targeted therapies. However, challenges remain in individualizing treatment and risk stratification due to modifying effects of common genetic variation and environmental factors. Further research is needed to understand the mechanisms that drive disease expression in order to enable disease prevention.
What Can We Learn From Children
TL;DR: Cardiac tissue from a biobank of pediatric and adult transplant recipients is used to elucidate unique properties of pediatric cardiomyopathy that could guide therapeutic strategies and support the hypothesis that pro-fibrotic macrophages may not play a role in pediatric remodeling.
Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure
Gregor Poglajen,Jus Ksela,Sabina Frljak,Gregor Zemljic,Elizabeta Boznar Alic,Andraz Cerar,Bojan Vrtovec +6 more
TL;DR: In patients with chronic heart failure undergoing CD34+ cell therapy, a decrease in galectin-3 plasma levels is associated with beneficial response to this treatment modality, and in nonresponders, an increase in gal-3 occurred.
Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life
Aaron J. Cohen,Kanako Teramoto,Kanako Teramoto,Brian Claggett,L. E.O. Buckley,Scott D. Solomon,Christie M. Ballantyne,Elizabeth Selvin,Amil M. Shah +8 more
TL;DR: In this article, the association of accumulated inflammation from mid-to late life with late-life risk of cardiac dysfunction and heart failure (HF) is limited, and these relationships are attenuated after adjusting for HF risk factors.
References
Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial
TL;DR: Short-term TNF&agr; antagonism with infliximab did not improve and high doses (10 mg/kg) adversely affected the clinical condition of patients with moderate-to-severe chronic heart failure.
1.5K
Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
Douglas L. Mann,John J.V. McMurray,Milton Packer,Karl Swedberg,Jeffrey S. Borer,Wilson S. Colucci,Jacques Djian,Helmut Drexler,Arthur M. Feldman,Lars Køber,Henry Krum,Peter Liu,Markku S. Nieminen,Luigi Tavazzi,Dirk J. van Veldhuisen,Anders Waldenström,Marshelle Warren,Arne Westheim,Faiez Zannad,Thomas Fleming +19 more
TL;DR: The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.
1.2K
Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites.
R Bravo,H Macdonald-Bravo +1 more
TL;DR: It was shown that the staining patterns of the replicon clusters and their order of appearance throughout the S phase are identical to those observed for cyclin, demonstrating that cyclin is tightly associated to the sites of DNA replication and that it must have a fundamental role in DNA synthesis in eukaryotic cells.
Intracellular functions of galectins
TL;DR: This review summarizes the intracellular activities displayed by several galectins and discusses the possible underlying mechanisms.
694
Extracellular functions of galectin-3
TL;DR: Galectin-3 has been suspected of modulating cell to extracellular matrix interactions in a novel fashion ever since it was first described but the rapid accumulation of research data in just the last 8 years alone has completely changed the perspective of this multifunctional protein.
387